

Consumer Product Safety Commission

§ 1702.2

CFR 1700.1(b)(2)), the term *household substance* is defined as “any substance which is customarily produced or distributed for sale for consumption or use, or customarily stored, by individuals in or about the household * * *.” The Commission has issued requirements for special packaging for certain hazardous substances at 16 CFR 1700.14(a). Unless otherwise indicated in the requirements for specific hazardous substances, the Commission interprets the term “household substance” as only applying to these hazardous substances when packaged in containers with a capacity of less than 5 gallons. As a result, unless otherwise specified, the hazardous substances at 16 CFR 1700.14(a) are not required to be in special packaging when packaged in containers of 5 gallons or more.

(Secs. 2, 5, 7, 9, Pub. L. 91-601; 94 Stat. 1670-1674 (15 U.S.C. 1471, 1474, 1476, 1478); sec. 30(a), Pub. L. 92-573, 86 Stat. 1231 (15 U.S.C. 2079(a)) [43 FR 53712, Nov. 17, 1978]

PART 1702—PETITIONS FOR EXEMPTIONS FROM POISON PREVENTION PACKAGING ACT REQUIREMENTS; PETITION PROCEDURES AND REQUIREMENTS

Sec.

- 1702.1 Purpose and policy.
- 1702.2 Procedural requirements and recommendations.
- 1702.3 Substantive requirements.
- 1702.4 Petitions with insufficient or incomplete information.
- 1702.5 Failure to supply adverse information.
- 1702.6 Trade secrets and other confidential information.
- 1702.7 Justification for the exemption.
- 1702.8 Human experience data.
- 1702.9 Relevant experimental data.
- 1702.10 Human experimental data involving the testing of human subjects.
- 1702.11 Product specifications.
- 1702.12 Packaging specifications.
- 1702.13 Labeling and packaging samples.
- 1702.14 Marketing history.
- 1702.15 Petitions alleging the incompatibility of child resistant packaging with the particular substance petitioned for exemption.
- 1702.16 Petitions requesting an exemption for a drug or a new drug.
- 1702.17 Granting petitions.
- 1702.18 Denying petitions.
- 1702.19 Effect of filing petition.

AUTHORITY: 15 U.S.C. 1471(4), 1472, 1474, 1269(a), 2079(a); 21 U.S.C. 371(a).

SOURCE: 45 FR 13064, Feb. 28, 1980, unless otherwise noted.

§ 1702.1 Purpose and policy.

(a) Section 1700.14(a) of part 1700 lists household substances the Consumer Product Safety Commission requires, under section 3(a)(1) of the Poison Prevention Packaging Act of 1970, 15 U.S.C. 1472, to be contained in special packaging to protect children from serious personal injury or serious illness resulting from handling, using, or ingesting such substances. There may be occasions, however, when the Commission determines that a particular substance should be exempt from special packaging requirements.

(b) The Commission may, either on its own initiative or upon the petition of any interested person, amend the regulation at §1700.14(a) by exempting a substance or category of substances from special packaging requirements. The purpose of these rules is to provide procedures and requirements for submitting petitions for exemption from special packaging requirements.

§ 1702.2 Procedural requirements and recommendations.

(a) *Requirements.* To be considered a petition for exemption from special packaging requirements under this part a document filed under this part must:

(1) Be mailed to the Office of the Secretary, Consumer Product Safety Commission, Washington, D.C. 20207, or delivered to the Office of the Secretary, Consumer Product Safety Commission, 4330 East West Highway, Bethesda, MD 20814,

(2) Be written in the English language,

(3) Contain the name and address of the petitioner,

(4) Contain an explicit request for exemption from special packaging requirements,

(5) Identify the category of substances under §1700.14(a) from which the exemption is sought, and

(6) Identify the particular substance for which the exemption is sought.

§ 1702.3

(b) *Failure to meet requirements.* Where a submission fails to meet all of the requirements of paragraph (a) of this section, the Office of the Secretary shall notify the person submitting it, describe the deficiency, and explain that the petition may be resubmitted when the deficiency is corrected.

(c) *Procedural recommendations.* The following are procedural recommendations to help the Commission in its consideration of petitions. The Commission requests, but does not require, that petitions filed under this part:

- (1) Be typewritten,
- (2) Include the word “petition” in a heading preceding the text,
- (3) Include the telephone number of the petitioner, and
- (4) Be accompanied by at least five (5) copies of the petition.

[45 FR 13064, Feb. 28, 1980, as amended at 62 FR 46668, Sept. 4, 1997]

§ 1702.3 Substantive requirements.

(a) A petition filed under this part shall include the information required by this part, or a satisfactory explanation for the absence of the information. As provided by § 1702.4, a petition which is not complete may be closed. To be considered complete, a petition shall include the following:

- (1) A statement of the justification for the exemption in accordance with § 1702.7,
- (2) All reasonably available human experience data, reasonably available relevant experimental data (both human and animal), product and packaging specifications, labeling, and marketing history, in accordance with §§ 1702.8 through 1702.14,

(b) As used in this regulation, “reasonably available” information is data in the petitioner’s possession; data that has previously been generated by the petitioner, and data that is obtainable from such sources as: Reports from Poison Control Centers; reports of adverse reactions that have been submitted to the petitioner; the medical, pharmacological, and toxicological literature; and information required by the FDA for an Investigational Exemption for a New Drug (IND) or a New Drug Application (NDA).

16 CFR Ch. II (1–13 Edition)

§ 1702.4 Petitions with insufficient or incomplete information.

If a petition is submitted that is not complete and does not explain the reason for the absence of the information, the Commission shall afford the petitioner a reasonable opportunity to provide additional information. If the required information is not submitted to the Commission, or if the petitioner does not satisfactorily explain the absence of the information within a reasonable time, the petition shall be closed if insufficient or incomplete information has been submitted to enable the Commission to evaluate the merits of the exemption request.

§ 1702.5 Failure to supply adverse information.

Failure to obtain and provide the Commission with all reasonably available information that the petitioner knows is unfavorable or could reasonably expect to be unfavorable to the petition shall result in the denial of the petition.

§ 1702.6 Trade secrets and other confidential information.

Where a petition contains material that the petitioner believes should be exempt from public disclosure under the Freedom of Information Act, 5 U.S.C. 552, the petitioner shall comply with the requirements of 16 CFR part 1015, the Commission’s regulation under the Freedom of Information Act concerning requests for treatment as exempt material. The Commission shall act upon any request for treatment as exempt material in accordance with the provisions of 16 CFR part 1015.

§ 1702.7 Justification for the exemption.

The justification for the exemption, required under § 1702.3, shall explain the reason for the exemption based on one or more of the following grounds:

- (a) If the justification is based on a lack of need for special packaging to protect young children from serious injury or illness from the substance, the justification shall state how the lack of toxicity and lack of adverse human experience for the substance clearly supports granting the exemption.